Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Severe Persistent Asthma AND Asthma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    127 result(s) found for: Severe Persistent Asthma AND Asthma. Displaying page 1 of 7.
    1  2  3  4  5  6  7  Next»
    EudraCT Number: 2014-004940-36 Sponsor Protocol Number: EFC13579 Start Date*: 2015-07-20
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) Outside EU/EEA IT (Completed) DE (Completed) ES (Completed) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2005-000532-25 Sponsor Protocol Number: D5890L00014 Start Date*: 2005-06-15
    Sponsor Name:AstraZeneca AB
    Full Title: A comparison of Symbicort Single inhaler Therapy (Symbicort Turbuhaler 160/4.5 mg, 1 inhalation b.i.d. plus as needed) and conventional best practice for the treatment of persistent asthma in adole...
    Medical condition: This is a Phase IIIB trial to be conducted in patients with persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003553 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed) LT (Completed) LV (Completed) CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-001681-40 Sponsor Protocol Number: BY9010/IT-101 incl. amendment 1 Start Date*: 2004-10-25
    Sponsor Name:ALTANA Pharma AG
    Full Title: Comparison of inhaled ciclesonide (640 µg/day) and fluticasone propionate (1000 µg/day) in patients with moderate and severe per-sistent asthma
    Medical condition: asthma
    Disease: Version SOC Term Classification Code Term Level
    5.1 10003553 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-005030-19 Sponsor Protocol Number: VR506/2/004 Start Date*: 2012-08-17
    Sponsor Name:Vectura Limited
    Full Title: A randomised double-blind, parallel group, dose-ranging study to evaluate the efficacy and safety of three different total daily doses of fluticasone propionate inhaled from a new dry powder inhale...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) PL (Completed) BG (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000520-18 Sponsor Protocol Number: CQMF149E2203 Start Date*: 2012-10-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo controlled, 12-week treatment, parallel-group study to assess the efficacy, safety and pharmacokinetics of indacaterol acetate (75 and 150 μg o.d.) ...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    15.1 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SK (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006512-30 Sponsor Protocol Number: D5890L00022 Start Date*: 2007-01-15
    Sponsor Name:AstraZeneca AB
    Full Title: A Pan-European, open label, randomised study comparing the efficacy and cost-effectiveness of Symbicort Maintenance and Reliever Therapy (Symbicort SMART) using a maintenance dose of Symbicort 160/...
    Medical condition: Persistent asthma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) GR (Completed) IS (Completed) NL (Completed) FR (Completed) ES (Completed) IE (Completed) DK (Completed) FI (Completed) BE (Completed) IT (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002766-37 Sponsor Protocol Number: 2003-72-DPI-6 Start Date*: 2005-01-12
    Sponsor Name:HEXAL AG (Project Management on behalf of the Sponsor: HEXAL Pharmaforschung GmbH
    Full Title: Open-label, multi-center, non-controlled follow-up study over 3-months on the safety of Formoterol Easyhaler® in approximately 35 asthmatic pediatric patients initially treated in study 2003-51-DPI-2
    Medical condition: Moderate to severe asthma bronciale in pediatric
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003555 LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004191-13 Sponsor Protocol Number: AVT-01/2/AST/04 Start Date*: 2007-01-23
    Sponsor Name:Avontec GmbH
    Full Title: Efficacy and safety of AVT-01 10 mg single dose in patients with mild asthma challenged with inhaled tumor necrosis factor alpha – A double-blind, randomized, placebo-controlled clinical study
    Medical condition: Male outpatients aged 18 - 65 with moderate persistent atopic asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003638 Atopic asthma LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001242-17 Sponsor Protocol Number: BY9010/M1-207 Start Date*: 2005-07-18
    Sponsor Name:ALTANA Pharma AG
    Full Title: Efficacy and Safety – Study by ALTANA on Ciclesonide in Pre-school Asthma Patients
    Medical condition: asthma bronchiale
    Disease: Version SOC Term Classification Code Term Level
    5.1 10003553 llt
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-004932-20 Sponsor Protocol Number: 1311.14 Start Date*: 2015-06-05
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 w...
    Medical condition: Severe Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) NL (Completed) DE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005926-22 Sponsor Protocol Number: FLT3501 Start Date*: 2007-03-14
    Sponsor Name:Mundipharma Research Ltd.
    Full Title: An open, randomised, parallel group, multicentre study to compare the efficacy and safety of FlutiForm pMDI vs Seretide pMDI in adult subjects with mild to moderate-severe persistent, reversible as...
    Medical condition: Asthma bronchial
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003555 Asthma bronchial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-001514-33 Sponsor Protocol Number: BUSAL-III-05-1 Start Date*: 2006-06-05
    Sponsor Name:Laboratories SMB S.A.
    Full Title: A phase III, randomized, parallel group study to compare the therapeutic efficacy of SMB BUDESONIDE-SALMETEROL DPI capsule 300/25μg BID delivered by the AXAHALER® versus SERETIDE® DISKUS® 500/50μg ...
    Medical condition: Diagnosis of moderate to severe persistent asthma
    Disease: Version SOC Term Classification Code Term Level
    8.0 10003553 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002078-45 Sponsor Protocol Number: FG-506-17-05 Start Date*: 2004-11-01
    Sponsor Name:Fujisawa GmbH
    Full Title: A RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TACROLIMUS MDI AS ADD-ON THERAPY TO ICS AND LABA IN MODERATE TO SEVERE PERSISTENT ASTHMATIC PATIENTS
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10003553 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2008-007244-33 Sponsor Protocol Number: LPA112046 Start Date*: 2009-04-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: The efficacy of orally administered GSK2190915 as an add-on to current therapy in subjects with moderate to severe asthma who have elevated sputum neutrophils
    Medical condition: Moderate to severe asthma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002375-11 Sponsor Protocol Number: EFC13995 Start Date*: 2022-07-20
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Randomized, Double Blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy and Safety of Dupilumab in Patients with Persistent Asthma
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001103-36 Sponsor Protocol Number: 2013RC01 Start Date*: 2013-05-27
    Sponsor Name:Tayside Medical Sciences Centre on behalf of University of Dundee & NHS Tayside
    Full Title: Randomised controlled single and chronic dosing crossover comparison of extra fine particle formoterol and coarse particle salmeterol in asthmatic patients with persistent small airways dysfunction
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-001869-33 Sponsor Protocol Number: D3551C00001 Start Date*: 2013-01-18
    Sponsor Name:AstraZeneca AB
    Full Title: A 6-month, Randomised, Double-blind, Placebo-controlled, Multi-centre, Parallel-group, Phase II Study with an Optional Safety Extension Treatment Period up to 6 months, to Evaluate the Efficacy, Sa...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) SK (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-002084-27 Sponsor Protocol Number: cro-725 Start Date*: 2007-10-02
    Sponsor Name:Imperial College
    Full Title: The pharmacokinetics and anti-inflammatory effects of prednisolone in severe asthma.
    Medical condition: This study is designed to look why patients with severe asthma fail to respond to oral corticosteroids in the same way as patients with non-severe disease.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020803-63 Sponsor Protocol Number: AB07015 Start Date*: 2010-10-18
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, 2-parallel groups, Phase 3 study to compare the efficacy and the safety of masitinib at 6 mg/kg/day versus placebo in the t...
    Medical condition: Severe Persistent Asthma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003553 Asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prohibited by CA) CZ (Completed) BG (Completed) DE (Prematurely Ended) SK (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000683-99 Sponsor Protocol Number: CL-9709-301-RD Start Date*: 2011-09-20
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: Control of moderate or severe asthma with 160, 320 and 640μg ciclesonide/day. A one-year randomised, double-blind, multicenter trial.
    Medical condition: moderate or severe asthma
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038738 - Respiratory, thoracic and mediastinal disorders 10003553 Asthma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:16:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA